Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label gliosis. Show all posts
Showing posts with label gliosis. Show all posts

Tuesday, October 24, 2017

Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells

Sounds promising. You will have to have your doctor contact their stroke research partners to get this tested in humans. If they don't have partners your stroke department head is incompetent along with your stroke hospital president.  With no partners they are just inert and useless doctors,

WAITING FOR SOMEONE ELSE TO SOLVE THE PROBLEM?

I could see significant problems getting through the skull to actually affect the brain itself. But that is for your doctor and researchers to solve. 

Photobiomodulation therapy promotes neurogenesis by improving post-stroke local microenvironment and stimulating neuroprogenitor cells








Highlights

PBM alleviates behavioral deficits after PT stroke.
PBM decreases cortical infarct size and increases neuronal survival.
PBM promotes cortical neurogenesis after PT stroke.
PBM inhibits local inflammatory status and promotes mitochondrial function.
PBM promotes proliferation and differentiation of neuroprogenitor cells.

Abstract

Recent work has indicated that photobiomodulation (PBM), also known as low-level laser/light therapy (LLLT), may beneficially alter the pathological status of several neurological disorders, although the mechanism currently remains unclear. The current study was designed to investigate the beneficial effect of PBM on behavioral deficits and neurogenesis in a photothrombotic (PT) model of ischemic stroke in rats. From day 1 to day 7 after the establishment of PT model, 2-minute daily PBM (CW, 808 nm, 350 mW/cm2, total 294 J at scalp level) was applied on the infarct injury area (1.8 mm anterior to the bregma and 2.5 mm lateral from the midline). Rats received intraperitoneal injections of 5-bromodeoxyuridine (BrdU) twice daily (50 mg/kg) from day 2 to 8 post-stoke, and samples were collected at day 14. We demonstrated that PBM significantly attenuated behavioral deficits and infarct volume induced by PT stroke. Further investigation displayed that PBM remarkably enhanced neurogenesis and synaptogenesis, as evidenced by immunostaining of BrdU, Ki67, DCX, MAP2, spinophilin, and synaptophysin. Mechanistic studies suggested beneficial effects of PBM were accompanied by robust suppression of reactive gliosis and the production of pro-inflammatory cytokines. On the contrary, the release of anti-inflammatory cytokines, cytochrome c oxidase activity and ATP production in peri-infarct regions were elevated following PBM treatment. Intriguingly, PBM could effectively switch an M1 microglial phenotype to an anti-inflammatory M2 phenotype. Our novel findings indicated that PBM is capable of promoting neurogenesis after ischemic stroke. The underlying mechanisms may rely on: 1) promotion of proliferation and differentiation of internal neuroprogenitor cells in the peri-infarct zone; 2) improvement of the neuronal microenvironment by altering inflammatory status and promoting mitochondrial function. These findings provide strong support for the promising therapeutic effect of PBM on neuronal repair following ischemic stroke.

Monday, August 10, 2015

Astrocyte reactivity after brain injury—: The role of galectins 1 and 3

So should we get galectin 3 delivered to the brain after a stroke to repair astrocytes? Whom do we contact to answer this very simple question? Or will 50 years pass again because we have no one following and executing a stroke strategy?
http://onlinelibrary.wiley.com/doi/10.1002/glia.22898/full

  1. Swetlana Sirko1,2,
  2. Martin Irmler3,
  3. Sergio Gascón1,2,
  4. Sarah Bek1,
  5. Sarah Schneider1,2,
  6. Leda Dimou1,2,
  7. Jara Obermann4,
  8. Daisylea De Souza Paiva1,5,
  9. Francoise Poirier6,
  10. Johannes Beckers3,7,
  11. Stefanie M. Hauck4,
  12. Yves-Alain Barde8 and
  13. Magdalena Götz1,2,9,*
Article first published online: 6 AUG 2015
DOI: 10.1002/glia.22898

SEARCH

Keywords:

  • glia proliferation;
  • neurosphere;
  • genomewide analysis

Abstract

Astrocytes react to brain injury in a heterogeneous manner with only a subset resuming proliferation and acquiring stem cell properties in vitro. In order to identify novel regulators of this subset, we performed genomewide expression analysis of reactive astrocytes isolated 5 days after stab wound injury from the gray matter of adult mouse cerebral cortex. The expression pattern was compared with astrocytes from intact cortex and adult neural stem cells (NSCs) isolated from the subependymal zone (SEZ). These comparisons revealed a set of genes expressed at higher levels in both endogenous NSCs and reactive astrocytes, including two lectins—Galectins 1 and 3. These results and the pattern of Galectin expression in the lesioned brain led us to examine the functional significance of these lectins in brains of mice lacking Galectins 1 and 3. Following stab wound injury, astrocyte reactivity including glial fibrillary acidic protein expression, proliferation and neurosphere-forming capacity were found significantly reduced in mutant animals. This phenotype could be recapitulated in vitro and was fully rescued by addition of Galectin 3, but not of Galectin 1. Thus, Galectins 1 and 3 play key roles in regulating the proliferative and NSC potential of a subset of reactive astrocytes. GLIA 2015.

Introduction

Reactive gliosis is a widespread reaction of glial cells to pathological processes in the brain. It involves astrocytes, NG2 glia, and microglia that mediate beneficial and adverse effects, such as wound closure and scar formation, respectively (Kettenmann et al., 2011). Recent work indicates a striking heterogeneity in the reaction of each type of glial cells (Anderson et al., 2014; Burda and Sofroniew, 2014; Dimou and Götz, 2014). This could be best demonstrated by live in vivo imaging, which revealed a surprisingly heterogeneous reaction of astrocytes reacting to stab wound injury in the adult murine cerebral cortex gray matter (GM), with some astrocytes hardly reacting at all, others polarizing toward the injury site and yet others proliferating and generating two daughter astrocytes (Bardehle et al., 2013). Furthermore, clonal analysis demonstrated that the differential reaction of astrocyte subtypes is seemingly related to their distinct developmental origin (Martín-López et al., 2013). In view of this heterogeneity, it is now important to address the mechanisms regulating the reaction of these distinct astrocyte subsets after brain injury.
Astrocytes resuming cell division after lesion are of particular importance, as proliferation is the only means to increase astrocyte numbers at the injury site in the cerebral cortex GM (Bardehle et al., 2013). Indeed, proliferating astrocytes are critical for restricting the injury size and the number of infiltrating cells and inflammation, since their elimination has been shown to aggravate brain damage after lesion (Burda and Sofroniew, 2014). Interestingly, astrocyte proliferation in the GM is highly injury-dependent and does not occur upon amyloid plaque deposition or even pronounced neuronal cell death, in spite of profound microglia activation and proliferation (Behrendt et al., 2013; Sirko et al., 2013). Instead, it is selectively elicited upon injury involving alterations of the blood brain barrier, such as traumatic, ischemic, and demyelinating injuries (Behrendt et al., 2013; Dimou and Götz, 2014; Gadea et al., 2008; Götz and Sirko, 2013; Kamphuis et al., 2012). These injury-specific differences led to the identification of signals regulating reactive astrocyte proliferation, including endothelin-1, sonic hedgehog and fibroblast growth factor (FGF) signaling (Gadea et al., 2008; Kang et al., 2014; Sirko et al., 2013; Zamanian et al., 2012). To obtain a more comprehensive view on the key regulators of reactive astrocyte proliferation, we set out to examine the pattern of gene expression in reactive astrocytes at the peak of their proliferation following stab wound injury in comparison to nonproliferative astrocytes in the intact adult cerebral cortex GM.
As a subset of proliferating reactive astrocytes acquire neural stem cell (NSC) potential after injury, monitored by the ability to form multipotent, self-renewing neurospheres (Buffo et al., 2008; Grande et al, 2013; Sirko et al., 2013), this prompts the question how much of the gene expression changes of reactive astrocytes may be shared with NSCs. Only genomewide expression analysis comparing reactive astrocytes, NSCs and nonreactive astrocytes allow determining the degree of similarity between NSCs and reactive astrocytes and the extent of injury-specific gene expression.
A small number of candidates shared by reactive astrocytes and endogenous NSCs have already been identified and tested, including glial fibrillary acidic protein (GFAP), Nestin, Musashi, DSD1-proteoglycan, and Tenascin-C (for review, see Götz et al., 2015; Robel et al., 2011; Sirko et al., 2009). However, these proteins also appear in injury conditions without reactive proliferation of astrocytes and/or neurosphere formation (Kamphuis et al., 2012; Robel at al., 2011), thus emphasizing the need for additional molecular insights. Toward this aim, we compared genomewide expression of astrocytes reacting to stab wound with astrocytes from the intact adult GM, as well as an existing expression profile of endogenous NSCs located in the adult SEZ (Beckervordersandforth et al., 2010).

More at link.

Thursday, March 15, 2012

Attenuating inflammation but stimulating both angiogenesis and neurogenesis using hyperbaric oxygen in rats with traumatic brain injury

Don't make any assumptions about this being useful for survivors.
http://journals.lww.com/jtrauma/Abstract/2012/03000/Attenuating_inflammation_but_stimulating_both.15.aspx

Abstract

BACKGROUND: Inflammation, angiogenesis, neurogenesis, and gliosis are involved in traumatic brain injury (TBI). Several studies provide evidence supporting the neuroprotective effect of hyperbaric oxygen (HBO2) therapy in TBI. The aim of this study was to ascertain whether inflammation, angiogenesis, neurogenesis, and gliosis during TBI are affected by HBO2 therapy.

METHODS: Rats were randomly divided into three groups: TBI + NBA (normobaric air: 21% O2 at 1 absolute atmospheres), TBI + HBO2, and Sham operation + NBA. TBI + HBO2 rats received 100% O2 at 2.0 absolute atmospheres for 1 hr/d for three consecutive days. Behavioral tests and biochemical and histologic evaluations were done 4 days after TBI onset.

RESULTS: TBI + NBA rats displayed: (1) motor and cognitive dysfunction; (2) cerebral infarction and apoptosis; (3) activated inflammation (evidenced by increased brain myeloperoxidase activity and higher serum levels of tumor necrosis factor-α); (4) neuronal loss (evidenced by fewer NeuN-positive cells); and (5) gliosis (evidenced by more glial fibrillary protein-positive cells). In TBI + HBO2 rats, HBO2 therapy significantly reduced TBI-induced motor and cognitive dysfunction, cerebral infarction and apoptosis, activated inflammation, neuronal loss, and gliosis. In addition, HBO2 therapy stimulated angiogenesis (evidenced by more bromodeoxyuridine-positive endothelial and vascular endothelial growth factor-positive cells), neurogenesis (evidenced by more bromodeoxyuridine-NeuN double-positive and glial cells-derived neurotrophic factor-positive cells), and overproduction of interleukin-10 (an anti-inflammatory cytokine).

CONCLUSIONS: Collectively, these results suggest that HBO2 therapy may improve outcomes of TBI in rats by inhibiting activated inflammation and gliosis while stimulating both angiogenesis and neurogenesis in the early stage.